The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma

Cancer

Volumn 89, Issue 9, 2000, Pages 2006-2017

  Shahin, Mark S ^a   Hughes, Jonathon H ^a   Sood, Anil K ^a   Buller, Richard E ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Cox proportional hazard model; Mutation; Ovarian carcinoma; p53; Sequencing; Survival

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 0034332322     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20001101)89:9<2006::AID-CNCR18>3.3.CO;2-Z     Document Type: Article

References (63)

1. Cancer statistics, 1999
2. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
3. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13
4. Trends in United States ovarian cancer mortality, 1979-1995
5. Epithelial ovarian carcinoma
6. Participation of p53 protein in the cellular response to DNA damage
7. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents
8. p53 Functions as a cell cycle control protein in osteosarcomas
9. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
10. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
11. The 1993 Walter Hubert Lecture: The role of the p53 tumour-suppressor gene in tumorigenesis
12. Inactivation of p53 enhances sensitivity to multiple chemotherapy agents
13. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma
14. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy
15. p53 Status and the efficacy of cancer therapy in vivo
16. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenograffs
17. p53 Tumor suppressor gene therapy for cancer
18. Retrovirus-mediated wild-type gene transfer to tumors of patients with lung cancer
19. A phase I study of gene therapy with recombinant p53 in recurrent ovarian cancer
20. p53 And behaviour of colorectal cancer
21. p53 Point mutation and survival in colorectal cancer
22. Prognostic value of p53 genetic changes in colorectal cancer
23. p53 Mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinoma
24. p53 Nuclear protein overexpression in colorectal cancer: A dominant predictor of survival in patients with advanced hepatic metastasis
25. Prognostic significance of TP53 alterations in breast carcinoma
26. Bcl-2 and p53 protein expression in non-small cell lung cancers: Correlation with survival time
27. Prognostic value of Bcl-2 and p53 expression in urinary tract transitional cell cancer
28. An uncertain role for p53 gene alterations in human prostate cancers
29. TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc binding domains
30. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry
31. Analysis of p53 gene mutation by polymerase chain reaction-single stranded conformation polymorphism provided independent prognostic information in node-negative breast cancer
32. Overexpression and mutation of p53 in epithelial ovarian cancer
33. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer
34. p53 Expression in epithelial ovarian neoplasms: Relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry
35. p53 Gene mutations and protein accumulation in human ovarian cancer
36. Prognostic significance of p53 immunostaining in epithelial ovarian cancer
37. p53 Mutations in a series of epithelial ovarian cancers from U.K., and its prognostic significance
38. Mutant p53 protein overexpression is associated with poor outcome in patients with well and moderately differentiated ovarian carcinoma
39. The significance of p53 mutation and overexpression in ovarian cancer prognosis
40. p53 Protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma
41. DNA sequence analysis of exon 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies
42. Quantification of p53 in epithelial ovarian cancer
43. p53 Overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer
44. Immunophenotype of ovarian cancer as predictor of clinical outcome: Evaluation at primary surgery and second-look procedure
45. The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer
46. p53 Mutations and expression in ovarian cancers: Correlation with overall survival
47. Clinical significance of apoptosis-related factors p53, mdm2, and bcl-2 in advanced ovarian cancer
48. Changes in definitions of clinical staging for carcinoma of the cervix and ovary
49. An abundance of p53 null mutations in ovarian carcinoma
50. An efficient method for the extraction of DNA from formalin-fixed, paraffin-embedded tissue by sonication
51. SSCP and sequence analysis of p53 mutations in ovarian tumors
52. An Alu polymorphism intragenic to the TP53 gene
53. Simple sequence repeat polymorphism within the p53 gene
54. Characterization of a frequent polymorphism within the p53 gene
55. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis
56. p53 Allelotypes and enhanced detection of allelic loss in ovarian cancer: Lack of correlation with familial and clinical factors
57. Tumor-suppressor p53. Implications for tumor development and prognosis
58. Specificity of seven monoclonal anti-bodies against p53 evaluated with western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry
59. Heterogeneity in proliferation markers in colorectal cancer
60. Relationship between p53 mutation, p53 overexpression, and survival in advanced ovarian cancers treated on gynecologic oncology group protocols 114 and 132
61. P53 gene mutations in breast cancers in Midwestern US women: Null as well as missense-type mutations are associated with poor prognosis
62. Distant metastases in ovarian cancer: Association with p53 mutations
63. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumerigenic mutations